Security
Eupraxia Pharmaceuticals Inc · EPRX.WT.A
EPRX.WT.ATSXWarrantHistorical · closed Apr 20, 2026CIK 1581178Updated Nov 11, 2026
Current securities for this SEC filerEPRX · NASDAQEPRX · TSX
EPRX.WT.A price & chart
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 86,150,008Source | 34,942,355Source | 20,266,229Source | 19,122,249Source |
| Property, Plant and Equipment, NetUSD | 834,429Source | 357,893Source | 409,587Source | 443,464Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 80,563,482Source | 33,101,294Source | 19,341,756Source | 18,263,389Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 716,095Source | 258,074Source | — | — |
| Assets, CurrentUSD | 85,098,550Source | 34,436,678Source | 19,803,078Source | 18,589,007Source |
| Operating Lease, Right-of-Use AssetUSD | 152,697Source | 67,023Source | 46,660Source | 87,286Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 5,703,915Source | 3,103,386Source | 19,373,903Source | 11,914,395Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 195,406,895Source | 116,360,066Source | 92,913,585Source | 71,003,225Source |
| Retained Earnings (Accumulated Deficit)USD | -169,579,974Source | -131,003,831Source | -105,501,295Source | -77,280,499Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -2,044,137Source | -4,160,555Source | -2,706,552Source | -2,786,366Source |
| Stockholders' Equity Attributable to ParentUSD | 82,041,436Source | 33,404,803Source | 2,216,207Source | 7,786,525Source |
| Additional Paid in Capital, Common StockUSD | 28,520,331Source | 20,503,904Source | 17,510,469Source | 16,850,165Source |
| Liabilities and EquityUSD | 86,150,008Source | 34,942,355Source | 20,266,229Source | 19,122,249Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 5,628,005Source | 3,103,386Source | 19,373,903Source | 3,058,387Source |
| Operating Lease, Liability, CurrentUSD | 78,452Source | 71,859Source | 53,316Source | 50,403Source |
| Accounts Payable, CurrentUSD | 942,201Source | 376,541Source | 1,292,128Source | 1,814,067Source |
| Operating Lease, Liability, NoncurrentUSD | 75,910Source | 0Source | — | 51,303Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | -1,595,343Source | -1,565,834Source | -1,323,881Source | -578,671Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -38,605,652Source | -25,744,489Source | -28,966,006Source | -18,990,764Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 8,756,107Source | 3,223,464Source | 1,412,257Source | 1,433,812Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 431,449Source | 101,389Source | 103,710Source | -230,481Source |
| Deferred Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -28,552,218Source | -29,994,491Source | -20,683,623Source | -14,395,201Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -588,947Source | -75,159Source | -73,377Source | 9,834,371Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 76,058,540Source | 45,784,207Source | 21,013,970Source | 10,801,079Source |
| Repayments of Long-term DebtUSD | 0Source | 62,651Source | 79,441Source | 74,845Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 80,563,482Source | 33,101,294Source | 19,341,756Source | 18,263,389Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 0Source | 393,739Source | 598,046Source | 326,629Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 6,571,177Source | 2,120,887Source | 714,380Source | 1,052,758Source |
| DepreciationUSD | 237,717Source | 171,719Source | 155,527Source | 147,894Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -1,562,476Source | -159,214Source | 66,291Source | 240,547Source |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | -1,565,982Source | -156,087Source | 64,609Source | 223,709Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -2,562Source | 18,611Source | -4,846Source | -6,637Source |
| General and Administrative ExpenseUSD | 17,102,383Source | 10,924,135Source | 7,284,004Source | 3,987,598Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | -41,106,986Source | -25,928,093Source | — | — |
| Income Tax Expense (Benefit)USD | 19,091Source | 1,804Source | 36,423Source | 0Source |
| InterestExpenseNonoperatingUSD | 0Source | 603,573Source | — | — |
| Investment Income, InterestUSD | 1,412,516Source | 1,159,943Source | 862,969Source | 431,799Source |
| Net Income (Loss) Attributable to ParentUSD | -38,576,143Source | -25,502,536Source | -28,220,796Source | -18,489,629Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -29,509Source | -241,953Source | -745,210Source | -501,135Source |
| Nonoperating Income (Expense)USD | -152,522Source | 1,260,726Source | -1,082,354Source | -1,373,312Source |
| Operating ExpensesUSD | 38,434,039Source | 27,003,411Source | 27,847,229Source | 17,617,452Source |
| Proceeds from Issuance of Common StockUSD | 73,891,109Source | 22,853,391Source | 15,886,537Source | 10,636,577Source |
| Proceeds from Stock Options ExercisedUSD | 639,597Source | 25,245Source | 30,059Source | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 0Source | 0Source | 0Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -38,586,561Source | -25,742,685Source | -28,929,583Source | -18,990,764Source |
| Income Tax Expense (Benefit)USD | 19,091Source | 1,804Source | 36,423Source | 0Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -29,509Source | -241,953Source | -745,210Source | -501,135Source |
| Net Income (Loss) Attributable to ParentUSD | -38,576,143Source | -25,502,536Source | -28,220,796Source | -18,489,629Source |
| Earnings Per Share, BasicUSD per share | -1.03Source | -0.76Source | -1.17Source | -0.96Source |
| Earnings Per Share, DilutedUSD per share | -1.03Source | -0.76Source | -1.17Source | -0.96Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 39,956,133Source | 33,930,575Source | 24,146,623Source | 19,285,447Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 39,956,133Source | 33,930,575Source | 24,146,623Source | 19,285,447Source |
| Interest Expense (non-operating)USD | 0Source | 603,573Source | — | — |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | 19,091Source | 1,804Source | 36,423Source | 0Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -1,562,476Source | -159,214Source | 66,291Source | 240,547Source |
| General and Administrative ExpenseUSD | 17,102,383Source | 10,924,135Source | 7,284,004Source | 3,987,598Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | -41,106,986Source | -25,928,093Source | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -37,542,035Source | -25,501,790Source | -28,810,717Source | -18,925,281Source |
| Interest ExpenseUSD | 0Source | 603,573Source | 1,170,173Source | 982,856Source |
| Interest Expense, DebtUSD | 0Source | 601,637Source | 1,162,773Source | 958,669Source |
| Investment Income, InterestUSD | 1,412,516Source | 1,159,943Source | 862,969Source | 431,799Source |
| Labor and Related ExpenseUSD | 3,772,518Source | 3,093,027Source | 2,241,079Source | 1,641,049Source |
| Nonoperating Income (Expense)USD | -152,522Source | 1,260,726Source | -1,082,354Source | -1,373,312Source |
| Operating ExpensesUSD | 38,434,039Source | 27,003,411Source | 27,847,229Source | 17,617,452Source |
| Other General and Administrative ExpenseUSD | 1,786,631Source | 457,600Source | 389,210Source | 332,951Source |
| Preferred Stock Dividends, Income Statement ImpactUSD | 2,530,843Source | 425,557Source | — | — |
| Research and Development ExpenseUSD | 21,331,656Source | 16,079,276Source | 20,563,225Source | 13,629,854Source |
Filing attachments
d930016dex991.htm · 6-K · 2026-11-10
Exhibit 99.1 OPEN MARKET SALE AGREEMENT SM November 10, 2026 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 JEFFERIES SECURITIES, INC. 161 Bay Street, Suite 2600 Toronto, Ontario M5J 2S1 Ladies and Gentlemen: Eupraxia Pharmaceuticals Inc., a company continued under the laws of the Province of British Columbia (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC and Jefferies Securities, Inc., …
Read attachment ↗d98561dex991.htm · 6-K · 2026-11-10
Exhibit 99.1 EUPRAXIA PHARMACEUTICALS INC. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2026 (Unaudited and Expressed in U.S. Dollars) EUPRAXIA PHARMACEUTICALS INC. INDEX TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS September 30, 2026 and 2025 (Unaudited and Expressed in U.S. Dollars) CONTENTS CONDENSED CONSOLIDATED INTERIM BALANCE SHEETS 3 CONDENSED CONSOLIDATED INTERIM STATEME…
Read attachment ↗d98561dex992.htm · 6-K · 2026-11-10
Exhibit 99.2 EUPRAXIA PHARMACEUTICALS INC. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS For the Three and Nine Months ended September 30, 2026 1 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2026 This management’s discussion and analysis (“MD&A”) has been prepared as of November 10, 2026 and should be read in conjunction with the condensed consolidated interi…
Read attachment ↗d153391dex991.htm · 6-K · 2026-08-11
Exhibit 99.1 EUPRAXIA PHARMACEUTICALS INC. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2026 (Unaudited and Expressed in U.S. Dollars) EUPRAXIA PHARMACEUTICALS INC. INDEX TO CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS June 30, 2026 and 2025 (Unaudited and Expressed in U.S. Dollars) CONTENTS CONDENSED CONSOLIDATED INTERIM BALANCE SHEETS 3 CONDENSED CONSOLIDATED INTERIM STATEMENTS OF OPER…
Read attachment ↗d153391dex992.htm · 6-K · 2026-08-11
Exhibit 99.2 EUPRAXIA PHARMACEUTICALS INC. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS For the Three and Six Months ended June 30, 2026 1 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2026 This management’s discussion and analysis (“MD&A”) has been prepared as of August 11, 2026 and should be read in conjunction with the condensed consolidated interim financial st…
Read attachment ↗d133809dex991.htm · 6-K · 2026-05-12
Exhibit 99.1 EUPRAXIA PHARMACEUTICALS INC. CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED MARCH 31, 2026 (Unaudited and Expressed in U.S. Dollars) EUPRAXIA PHARMACEUTICALS INC. INDEX TO CONSOLIDATED FINANCIAL STATEMENTS March 31, 2026 and 2025 (Unaudited and Expressed in U.S. Dollars) CONTENTS CONSOLIDATED BALANCE SHEETS 3 CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS 4 CONSOLIDATED STATEMENTS OF CHANGE…
Read attachment ↗